While Centessa Pharmaceuticals shows promise with its ORX750 narcolepsy candidate, the article argues that Vertex Pharmaceuticals is a superior investment choice. Vertex has an established profitable business in cystic fibrosis, recent successful launches like Journavx and Casgevy, and a strong late-stage pipeline including zimislecel for Type 1 diabetes. Centessa, as a pre-revenue biotech, carries significantly higher risk despite its promising pipeline.

Commodore Capital significantly reduced its stake in Centessa Pharmaceuticals by selling 1.85 million shares (worth ~$46.86 million) in Q4, cutting its position from over 9% to 1.66% of assets. The sale comes as CNTA stock has surged 53.4% over the past year. The fund's move suggests capital redeployment amid Centessa's strategic shift toward focusing on its orexin franchise under new CEO Mario Accardi, raising questions about concentration risk versus the potential of the company's narrowed pipeline.

Nxera Pharma announced that its research collaboration partner Centessa Pharmaceuticals achieved an early development milestone with ORX489, an orexin receptor 2 agonist for neuropsychiatric disorders. The achievement triggers a $1.8 million milestone payment to Nxera, which will be recognized as revenue in Q1 2026.

Tanager Wealth Management exited its entire position in Centessa Pharmaceuticals (CNTA), selling 598,044 shares for approximately $14.5 million in the fourth quarter. The biotech stock had surged nearly 57% over the past year, significantly outperforming the S&P 500. The fund's exit reflects a strategy to reduce oversized positions after sharp rallies, despite Centessa's improving fundamentals including strong cash reserves and a recent CEO transition.

Centessa Pharmaceuticals presented preclinical data at the 64th ACNP Annual Meeting showing that OX2R activation with their agonist CNT-9982 reduced behavioral despair and enhanced wakefulness in animal models of major depressive disorder. The company plans to expand its OX2R agonist pipeline beyond rare hypersomnias into additional neuropsychiatric indications with high unmet clinical need.

TCG Crossover Management increased its stake in Centessa Pharmaceuticals by 245,664 shares in Q3, valuing the transaction at $38.1 million. The fund now holds over 3.1 million shares, making Centessa its fifth-largest holding, driven by promising early neurological drug data.

Centessa Pharmaceuticals announced a secondary offering of 11.63 million American Depositary Shares priced at $21.50 each, expecting to raise approximately $250 million for product pipeline development and corporate purposes.

Centessa Pharmaceuticals has priced a public offering of 11,627,907 American Depositary Shares at $21.50 per share, expecting to raise approximately $250 million to support its clinical-stage pharmaceutical development.

Centessa Pharmaceuticals is conducting an underwritten public offering of American Depositary Shares, with major investment banks like Jefferies and Leerink Partners managing the offering.

Nxera Pharma reported progress in its obesity and metabolic disease pipeline, achieved R&D milestones with AbbVie, and advanced cancer immunotherapy trials. The company experienced increased R&D expenses and a wider operating loss compared to the previous period.

Centessa Pharmaceuticals reported progress on its orexin receptor 2 (OX2R) agonist pipeline, with ongoing clinical trials for ORX750 and ORX142 targeting sleep-wake disorders and neurological conditions. The company expects key data readouts in 2025 and has sufficient cash runway into mid-2027.

Nxera Pharma reported increased revenues from PIVLAZ® and QUVIVIQ® in Japan, progress in partnered programs including Neurocrine's Phase 3 trial, and launched a new proprietary pipeline targeting obesity and weight management.